Psoriasis Clinical Trials

Showing 321-340 of 478 trials

A Trial of a Botanical Drug (EISO) for Treatment of Mild-to-Moderate Plaque Psoriasis

NCT03000608

This trial will be a double-blind, multi-center, randomized, placebo controlled study to evaluate the safety, tolerability, and efficacy of SAN021 study drug when administered for up to 42 days to adults between the ages of 18 to 65 years who have a clinical diagnosis of mild-to-moderate plaque psoriasis.

Plaque Psoriasis

Santalis Pharmaceuticals, Inc.69 participantsStarted May 2017

Austin, Texas, United States • San Antonio, Texas, United States • San Antonio, Texas, United States +1 more locations

COMPLETEDPHASE2

A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)

NCT02986373

This is an open-label extension (OLE) study to assess the efficacy, safety and tolerability of risankizumab in participants with psoriatic arthritis (PsA).

Psoriatic Arthritis

AbbVie145 participantsStarted Dec 2016

UNKNOWNNA

Fire Needle Therapy on Plaque Psoriasis With Blood Stasis Syndrome

NCT03953885

This study was designed as a multicenter, randomized, single blinded and placebo-controlled clinical trial. The aim of the study is to evaluate the clinical efficacy, safety and control of recurrence rate of plaque psoriasis with blood stasis syndrome, after treated with fire needle therapy.

Plaque Psoriasis

Shanghai Yueyang Integrated Medicine Hospital92 participantsStarted Jun 2019

Shijiazhuang, Hebei, China • Harbin, Heilongjiang, China • Nanchang, Jiangxi, China +2 more locations

A Trial of a Botanical Drug (EISO) for Treatment of Mild-to-Moderate Plaque Psoriasis

A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)

Fire Needle Therapy on Plaque Psoriasis With Blood Stasis Syndrome

Related Searches

Plaque Psoriasis Efficacy and Safety With Secukinumab

Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis

An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis

Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis

Mind-Body Approaches for Medical Conditions

Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.

Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis

Potential Research Study Participant Registry

Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test

Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene

A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)

Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.

An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients

Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis